{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.83688","value":"77.7750"},{"groupId":"OG001","spread":"4.00899","value":"75.7200"},{"groupId":"OG002","spread":"5.98330","value":"74.9354"},{"groupId":"OG003","spread":"7.94708","value":"74.6767"},{"groupId":"OG004","spread":"4.14997","value":"79.4139"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.59619","value":"-1.7500"},{"groupId":"OG001","spread":"12.87685","value":"10.1333"},{"groupId":"OG002","spread":"7.61104","value":"4.0182"},{"groupId":"OG003","spread":"12.34055","value":"16.9556"},{"groupId":"OG004","spread":"10.40833","value":"69.6667"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"Change from Baseline at end of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"Change from Baseline was calculated as the post-Baseline value minus the Baseline value.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.","id":"OG000","title":"Zilurgisertib 50 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.","id":"OG001","title":"Zilurgisertib 100 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.","id":"OG002","title":"Zilurgisertib 200 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.","id":"OG003","title":"Zilurgisertib 400 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.","id":"OG004","title":"Zilurgisertib 600 mg QD"}],"paramType":"MEAN","populationDescription":"Full Analysis Set-MDS. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"up to 950 days","title":"Change From Baseline in Hemoglobin at the End of Treatment","type":"SECONDARY","unitOfMeasure":"grams per liter"}